Evidence map›Paper›PMID 22076651›Full record

ArticleCellular and molecular life sciences : CMLS2012

Differential pathotropism of non-immortalized and immortalized human neural stem cell lines in a focal demyelination model.

Daniela Ferrari, Cristina Zalfa, Laura Rota Nodari, Maurizio Gelati, Luigi Carlessi, Domenico Delia, Angelo Luigi Vescovi, Lidia De Filippis

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03282760 (A Phase I Multicenter Study of Allogenic, Intracerebroventricular Human Neural Stem Cells Transplantation for the Experimental Treatment of Secondary Progressive Multiple Sclerosis Patients), which is not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03282760 phase1completednot on this mapstarted 2017, after this paper: background citation

A Phase I Multicenter Study of Allogenic, Intracerebroventricular Human Neural Stem Cells Transplantation for the Experimental Treatment of Secondary Progressive Multiple Sclerosis Patients

TypeinterventionalSponsorCasa Sollievo della Sofferenza IRCCSRan2017 to 2021Enrolled24ConditionsSecondary-progressive Multiple SclerosisArmsHuman Neural Stem Cells
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Generation of High-Yield, Functional Oligodendrocytes from a c-International journal of molecular sciences · 2021
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Stem cell therapy for amyotrophic lateral sclerosis.Cell regeneration (London, England) · 2015
    Article
  8. Review
  9. Review
  10. Advances in stem cell therapy for spinal cord injury.The Journal of clinical investigation · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Daniela FerrariDepartment of Biotechnology and Biosciences, Università Milano Bicocca, Milan, Italy. daniela.ferrari@unimib.it
Cristina Zalfa
Laura Rota Nodari
Maurizio Gelati
Luigi Carlessi
Domenico Delia
Angelo Luigi Vescovi
Lidia De Filippis
University of Milano-Bicocca · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITCasa Sollievo della Sofferenza · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cell therapy is reaching the stage of phase I clinical trials for post-traumatic, post-ischemic, or neurodegenerative disorders, and the selection of the appropriate cell source is essential. In order to assess the capacity of different human neural stem cell lines (hNSC) to contribute to neural tissue regeneration and to reduce the local inflammation after an acute injury, we transplanted GMP-grade non-immortalized hNSCs and v-myc (v-IhNSC), c-myc T58A (T-IhNSC) immortalized cells into the corpus callosum of adult rats after 5 days from focal demyelination induced by lysophosphatidylcholine. At 15 days from transplantation, hNSC and T-IhNSC migrated to the lesioned area where they promoted endogenous remyelination and differentiated into mature oligodendrocytes, while the all three cell lines were able to integrate in the SVZ. Moreover, where demyelination was accompanied by an inflammatory reaction, a significant reduction of microglial cells' activation was observed. This effect correlated with a differential migratory pattern of transplanted hNSC and IhNSC, significantly enhanced in the former, thus suggesting a specific NSC-mediated immunomodulatory effect on the local inflammation. We provide evidence that, in the subacute phase of a demyelination injury, different human immortalized and non-immortalized NSC lines, all sharing homing to the stem niche, display a differential pathotropism, both through cell-autonomous and non-cell autonomous effects. Overall, these findings promote IhNSC as an inexhaustible cell source for large-scale preclinical studies and non-immortalized GMP grade hNSC lines as an efficacious, safe, and reliable therapeutic tool for future clinical applications.

Indexed as

AnimalsCell LineCell SurvivalCell TransplantationDemyelinating DiseasesDisease Models, AnimalFemaleHumansNeural Stem CellsPhenotypeRats

Identifiers

PMID22076651
PMCPMC11115189
OpenAlexW2066990533

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.